Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127159282 | 12715928 | 2 | F | 20160907 | 20160906 | 20160919 | EXP | JP-ACCORD-043801 | ACCORD | MIYAMAE Y, SHIMIZU H, NAGANUMA A, AIBA M, TANAKA T, OGAWA T, ET AL. (A CASE OF RECTAL NEUROENDOCRINE CARCINOMA WITH METACHRONOUS LIVER METASTASIS TREATED WITH MULTIMODALITY THERAPY). GAN TO KAGAKU RYOHO. 2016 AUG;43(8):1009-13. | 62.00 | YR | F | Y | 0.00000 | 20160919 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127159282 | 12715928 | 1 | PS | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous bolus | FOLFOX4, BOLUS 400 MG/M2 DAY 1 OR 2, CHANGED TO CONTINUOUS INFUSION 600 MG/M2 22 HR DAY 1 OR 2 | U | 40743 | 400 | MG/M**2 | INFUSION | ||||||
| 127159282 | 12715928 | 2 | SS | IRINOTECAN | IRINOTECAN | 1 | 1 COURSE OF 28 DAYS, DAY 1, 8, 15 | U | 79068 | 50 | MG/M**2 | ||||||||
| 127159282 | 12715928 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | 1 COURSE OF 28 DAYS, AUC5 DAY 1 | U | 0 | ||||||||||
| 127159282 | 12715928 | 4 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | FOLFOX4, 1 COURSE OF 14 DAYS, 85 MG/M2 DAY 1 OR 2 | 0 | 85 | MG/M**2 | |||||||||
| 127159282 | 12715928 | 5 | SS | PANITUMUMAB | PANITUMUMAB | 1 | 1 COURSE OF 14 DAYS, 6 MG/KG DAY 1 | 0 | 6 | MG/KG | |||||||||
| 127159282 | 12715928 | 6 | SS | BEVACIZUMAB | BEVACIZUMAB | 1 | 1 COURSE OF 14 DAYS, 5 MG/KG (2 COURSE DAY FROM 10 MG/KG) DAY 1 | U | 0 | 5 | MG/KG | ||||||||
| 127159282 | 12715928 | 7 | C | FOLINIC ACID | LEUCOVORIN | 1 | FOLFOX4 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127159282 | 12715928 | 1 | Rectal cancer |
| 127159282 | 12715928 | 2 | Rectal cancer |
| 127159282 | 12715928 | 3 | Rectal cancer |
| 127159282 | 12715928 | 4 | Rectal cancer |
| 127159282 | 12715928 | 5 | Rectal cancer |
| 127159282 | 12715928 | 6 | Rectal cancer |
| 127159282 | 12715928 | 7 | Rectal cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127159282 | 12715928 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127159282 | 12715928 | Bone marrow failure | |
| 127159282 | 12715928 | Dermatitis acneiform | |
| 127159282 | 12715928 | Neuropathy peripheral | |
| 127159282 | 12715928 | Neutropenia | |
| 127159282 | 12715928 | Paronychia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127159282 | 12715928 | 1 | 201201 | 0 | ||
| 127159282 | 12715928 | 2 | 201109 | 0 | ||
| 127159282 | 12715928 | 3 | 201109 | 0 | ||
| 127159282 | 12715928 | 4 | 201201 | 0 | ||
| 127159282 | 12715928 | 5 | 201201 | 0 | ||
| 127159282 | 12715928 | 6 | 201206 | 0 |